Non Alcoholic Fatty Liver Disease

Overview

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), encompasses a spectrum from simple hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), fibrosis, and cirrhosis. Affecting roughly one in four adults globally, NAFLD is the hepatic manifestation of metabolic syndrome. The gut-liver axis — the bidirectional communication between intestinal microbiota and the liver via the portal vein — is increasingly recognized as central to NAFLD pathogenesis.

Microbiome Associations

The gut-liver axis ensures that the liver is the first organ exposed to microbial products translocating from the gut. In NAFLD, several microbiome patterns emerge:

  • proteobacteria enrichment — Increased Gram-negative bacteria elevate portal LPS levels, activating Kupffer cells via TLR4 and driving hepatic inflammation
  • akkermansia muciniphila depletion — Loss of this barrier-protective organism increases intestinal permeability and metabolic endotoxemia
  • blautia depletion — Reduced bile salt hydrolase (BSH) activity alters the bile acid pool, disrupting fxr signaling and impairing hepatic lipid metabolism
  • collinsella enrichment — Alters bile acid profiles, reducing hepatic bile acid synthesis via disrupted FXR signaling and promoting lipid accumulation
  • Ethanol-producing bacteria — Certain gut bacteria (e.g., Klebsiella pneumoniae) produce endogenous ethanol, contributing to hepatic injury even in the absence of alcohol consumption

Metal Associations

  • Cadmium — Disrupts the gut-liver axis in animal models, altering microbiome composition and accelerating hepatic steatosis. Cd-induced gut barrier damage increases portal LPS translocation.
  • Nickel — Increases hepatic glycogenolysis and elevates inducible nitric oxide synthase; in overweight women, nickel allergy prevalence reaches 59.7%, with NAFLD as a potential mediator
  • Arsenic — Environmental arsenic exposure correlates with NAFLD prevalence in epidemiological studies; arsenic disrupts hepatic lipid metabolism and promotes insulin resistance
  • Iron — Hepatic iron overload is common in MASH; iron catalyzes lipid peroxidation and drives progression from steatosis to steatohepatitis

Associated Conditions

NAFLD shares significant microbiome and metabolic overlap with other conditions:

  • obesity — Shared metabolic endotoxemia, Akkermansia depletion, and adipose tissue inflammation
  • type 2 diabetes — Bidirectional relationship; insulin resistance drives hepatic lipogenesis while NAFLD worsens glycemic control
  • atherosclerosis — NAFLD is an independent CVD risk factor; shared LPS-driven vascular inflammation
  • colorectal cancer — Altered bile acid metabolism (shifted secondary bile acid pool) connects hepatic and colonic pathology

Environmental Factors

Dietary patterns strongly influence NAFLD through the gut-liver axis. High-fat, high-fructose Western diets reduce microbial diversity, deplete SCFA-producing commensals, and increase intestinal permeability. Dietary cadmium exposure from contaminated grains, leafy vegetables, and shellfish provides a chronic metal burden that compounds the metabolic insult.

Open Questions

  • Does microbial endogenous ethanol production drive NAFLD independently of diet, or is it a marker of broader dysbiosis?
  • Can targeted restoration of BSH-expressing bacteria (Blautia, Lactobacillus) reverse hepatic steatosis through FXR reactivation?
  • What is the relative contribution of portal LPS versus bile acid dysregulation to NAFLD progression?

Cross-References

  • fxr — bile acid receptor whose disruption promotes hepatic steatosis
  • lipopolysaccharide — metabolic endotoxemia driver via portal vein
  • bile acid metabolism — microbial transformation controls hepatic signaling
  • obesity — shared metabolic and microbiome features
  • collinsella — enriched in NAFLD; disrupts FXR signaling
  • cadmium — gut-liver axis disruptor in animal models

References (8)

  1. . fujimoto 2022 human gut virome metabolic autoimmune
  2. . dejonge 2022 gut virome bacteriophage metabolic syndrome
  3. . fujimoto 2022 gut virome metabolic autoimmune
  4. . shukla 2023 arsenic gut bacteriome utero exposure
  5. . song 2025 microbiome targeted therapies nafld meta analysis
  6. . half 2019 fecal microbiome signatures pancreatic cancer
  7. . su 2025 altered gut microbiota erectile dysfunction pilot
  8. . tuohy 2014 dietary pro prebiotics cvd risk